Clinical Trial Update: LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial update on leukemia/lymphoma patients using LMP-specific T-cells for relapsed EBV-positive lymphoma; results posted for a completed study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Disease
• Non-hodgkin Lymphoma

Drugs mentioned

• LMP-specific T cells (LMP-specific T cells)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Hodgkin Disease, Non Hodgkin Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2020-02-07